Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2014 09:55 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201

NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
July 15, 2014 10:31 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201

NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy...
March 05, 2014 07:30 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200

NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...
February 18, 2014 07:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201

NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...